Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Evgeny Imyanitov

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

E.N. Imyanitov1, T.N. Sokolova1, G. Raskin2, A.O. Ivantsov1, A.G. Iyevleva1, A.P. Sokolenko1

Author affiliations

  • 1 Department Of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 - Saint-Petersburg/RU
  • 2 Department Of Pathology, A.M. Granov Russian Scientific Centre of Radiology and Surgical Technologies, Saint-Petersburg/RU
More

Resources

Abstract 2197

Background

HER2 oncogene amplification, being accompanied by its overexpression, is an established driver event in breast and gastric carcinomas. The functional role of HER2 in pathogenesis of other tumor types is less defined.

Methods

2401 archival samples of lung carcinomas (LC) and 1969 samples of colorectal carcinomas (CRC) were subjected to HER2 copy number analysis. Selected tumors with amplification of this oncogene were further subjected to HER2 immunohistochemistry and mRNA quantitation. In addition, the expression levels of some neighbouring genes located in 17q12-21 amplicon were analyzed.

Results

Frequency of HER2 amplification was similar in both groups, being 100/2401 (4.2%) in LC and 84/1969 (4.3%) in CRC, respectively. 10 (82%) out of 12 analyzed HER2-amplified CRCs demonstrated clear evidence for HER2 protein and mRNA overexpression, while this estimate approached to only 3 (27%) out of 11 for LCs. Expression analysis of GRB7, STARD3, and LASP1 revealed a statistically significant correlation between HER2 and STARD3 levels [r = 0.571, Spearman test]. High STARD3 expression was observed in HER2-amplified CRCs but not LCs [p = 0.03].

Conclusions

HER2 amplification is frequently accompanied by gene overexpression in colorectal but not lung adenocarcinomas. STARD3 gene belonging to 17q12-21 amplicon demonstrates evidence for activation in HER2-amplified colorectal neoplasms and therefore deserves further analysis.

Clinical trial identification

Legal entity responsible for the study

Evgeny Imyanitov.

Funding

Russian Science Foundation.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings